Added to YB: 2026-02-24
Pitch date: 2026-02-20
GSK [neutral]
GSK plc
Author Info
No bio for this author
Company Info
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
Market Cap
GBP 88.8B
Pitch Price
GBP 22.06
Price Target
N/A
Dividend
3.25%
EV/EBITDA
7.77
P/E
15.94
EV/Sales
3.14
Sector
Pharmaceuticals
Category
value
Theodosian Capital | Stocks Update 20/2/2026 - GSK – Pipeline progress
GSK (update): EU approved Exdensur/depemokimab for severe asthma w/ type 2 inflammation & chronic rhinosinusitis. 3m Europeans have severe asthma - meaningful addressable market. Pipeline expansion = clear commercial benefits. Cheap at 11.4x 2027 EPS consensus, 3.4% yield.
Read full article (1 min)